Remission in Schizophrenia: Critical and Systematic Review

REFERENCES

• Frese FJ, III, Knight EL, Saks E. Recovery from schizophrenia: with views of psychiatrists, psychologists, and others diagnosed with this disorder. Schizophr Bull 2009;35:370–80.
   PubMed Web of Science ®Google Scholar
• Adityanjee, Aderibigbe YA, Theodoridis D, Vieweg WVR. Dementia praecox to schizophrenia: the first 100 years. Psychiatry Clin Neurosci 1999;53:437–48.
   PubMed Web of Science ®Google Scholar
• Andreasen NC. A unitary model of schizophrenia: Bleuler's “fragmented phrene” as schizencephaly. Arch Gen Psychiatry 1999;56:781–7.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry 2006;67:1813–4.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011;24:114–21.
   PubMed Web of Science ®Google Scholar
• Curtis CE, Calkins ME, Grove WM, Feil KJ, Iacono WG. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry 2001;158:100–6.
   PubMed Web of Science ®Google Scholar
• Yen CF, Chen CS, Yeh ML, Yen JY, Ker JH, Yang SJ. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J Nerv Ment Dis 2002;190:847–9.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Jody D, Geisler S, Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369–76.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry 1997;6:212–8.
   PubMed Web of Science ®Google Scholar
• Eaton WWPD, Thara RMD, Federman ESD, Tien AMD. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J Nerv Ment Dis 1998;186:357–63.
   PubMed Web of Science ®Google Scholar
• Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 2000;157:808–15.
   PubMed Web of Science ®Google Scholar
• Emsley R, Rabinowitz J, Medori R. Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129–39.
   PubMed Web of Science ®Google Scholar
• Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006;86:300–8.
   PubMed Web of Science ®Google Scholar
• Miles AA, Heinrichs RW, Ammari N. “Real world” functioning in schizophrenia patients and healthy adults: assessing validity of the Multidimensional Scale of Independent Functioning. Psychiatry Res 2011;186:123–7.
   PubMed Web of Science ®Google Scholar
• Opler M, Yang L, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007;7:35.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Lançon C, Lancrenon S, The “Functional Remission of General Schizophrenia” (FROGS) scale: development and validation of a new questionnaire. Schizophr Res 2009;113:218–25.
   PubMed Web of Science ®Google Scholar
• Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007;33:792–6.
   PubMed Web of Science ®Google Scholar
• Kane JM, Leucht S. Issues in psychopharmacology. Schizophr Bull 2008;34:258.
   PubMed Web of Science ®Google Scholar
• Resnick SG, Fontana A, Lehman AF, Rosenheck RA. An empirical conceptualization of the recovery orientation. Schizophr Res 2005;75:119–28.
   PubMed Web of Science ®Google Scholar
• Opler MG, Yang LH, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007;7:35.
   PubMed Web of Science ®Google Scholar
• Menezes NM, Malla AM, Norman RM, Archie S, Roy P, Zipursky RB. A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis. Acta Psychiatr Scand 2009;120:138–46.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol 2009;12:1233–48.
   PubMed Web of Science ®Google Scholar
• Üçok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res 2011;189:33–7.
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S. Remission: what's in a name? Am J Psychiatry 2005;162:2393–4.
   PubMed Web of Science ®Google Scholar
• Docherty JP, Bossie CA, Lachaux B, Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007;22:51–5.
   PubMed Web of Science ®Google Scholar
• Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 2009;108:214–22.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol 2009;23:436–41.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJH, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006;67:1707–12.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry 2006;189:31– 5.
   PubMed Web of Science ®Google Scholar
• Ceskova E, Radovan P, Tomas K, Hana K. One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters). Neuropsychiatr Dis Treat 2007;3:153–60.
   PubMedGoogle Scholar
• Ceskova E, Prikryl R, Kasparek T. Outcome in males with first-episode schizophrenia: 7-year follow-up. World J Biol Psychiatry 2011;12:66–72.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, Niehaus DJH, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325–31.
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res 2008;106:281–5.
   PubMed Web of Science ®Google Scholar
• de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008;41:125–8.
   PubMed Web of Science ®Google Scholar
• Petersen L, Thorup A, Oqhlenschlaeger J, Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 2008;53:660–70.
   PubMed Web of Science ®Google Scholar
• Boter H, Peuskens J, Libiger J, Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009;115:97–103.
   PubMed Web of Science ®Google Scholar
• Üçok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res 2011;189:33–7.
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005;77:215–27.
   PubMed Web of Science ®Google Scholar
• Kissling W, Heres S, Lloyd K, Direct transition to long-acting risperidone: analysis of long-term efficacy. J Psychopharmacol 2005;19:15–21.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008;46:14–22.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007;94:99–106.
   PubMed Web of Science ®Google Scholar
• Kane JM, Crandall DT, Marcus RN, Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007;95: 143–50.
   PubMed Web of Science ®Google Scholar
• Eberhard J, Levander S, Lindstrom E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry 2009;50:200–8.
   PubMed Web of Science ®Google Scholar
• Rossi A, Bagala A, Del Curatolo V, Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2009;24:574–83.
   PubMed Web of Science ®Google Scholar
• Botha U, Koen L, Joska J, Hering L, Oosthuizen P. Assessing the efficacy of a modified assertive community-based treatment programme in a developing country. BMC Psychiatry 2010;10:73.
   PubMed Web of Science ®Google Scholar
• Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010;25: 220–9.
   PubMed Web of Science ®Google Scholar
• Meesters PD, Comijs HC, de Haan L, Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. Schizophr Res 2011;126:237–44.
   PubMed Web of Science ®Google Scholar
• Lasser RA, Nasrallah H, Helldin L, Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res 2007;96:223–31.
   PubMed Web of Science ®Google Scholar
• De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007;92:68–73.
   PubMed Web of Science ®Google Scholar
• van Os J, Burns T, Cavallaro R, Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91–5.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Jody D, Geisler S, Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369–76.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JMJ, Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544–9.
   PubMed Web of Science ®Google Scholar
• Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305–12.
   PubMed Web of Science ®Google Scholar
• Thompson J, Berk M, Dean O, Who's left? Symptoms of schizophrenia that predict clinical trial dropout. Hum Psychopharmacol 2011;26:609–13.
   PubMed Web of Science ®Google Scholar
• Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006;36:1349–62.
   PubMed Web of Science ®Google Scholar
• Schennach R, Obermeier M, Meyer S, Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 2012;63:87–90.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2011; Nov 29 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892–909.
   PubMed Web of Science ®Google Scholar
• Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286–90.
   PubMed Web of Science ®Google Scholar
• Kay SR, Flszbein A, Opfer LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Case M, Kinon BJ, Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 2011;187:42–8.
   PubMed Web of Science ®Google Scholar
• Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60: 1228–35.
   PubMed Web of Science ®Google Scholar
• Masand P, O'Gorman C, Mandel FS. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res 2011;126:174–83.
   PubMed Web of Science ®Google Scholar
• Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 2005;31:406–12.
   Web of Science ®Google Scholar
• Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand 2009;119:7–14.
   Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003;107:16–23.
   Web of Science ®Google Scholar
• Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20:293–301.
   PubMed Web of Science ®Google Scholar
• van Os J, Drukker M, a Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry 2006;163:2000–2.
   PubMed Web of Science ®Google Scholar
• Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin 2008;24:1399–405.
   PubMed Web of Science ®Google Scholar